Abstract
Sarcomas are a group of heterogeneous tumors that arise from mesenchymal tissue and account for approximately 1% of all adult solid malignancies diagnosed, although its incidence approaches 20% in pediatric cancers. Characterization of molecular abnormalities in patients with sarcomas, in particular the up-regulation of the receptor tyrosine kinase and the PI3K-AKT-mTOR pathway, loss or deletions of retinoblastoma (Rb) and p53 gene, increased VEGF expression and angiogenesis, dysregulation of apoptosis through Bcl-2 overexpression, along with oncogene mutations and activations, such as c-KIT in Gastrointestinal stromal tumors (GISTs), makes treatment with novel biological therapies a promising option. This review focuses on the molecular heterogeneity of soft tissue and bone sarcomas, novel biological therapies currently in clinical trials to target the various molecular pathways, and the potential biological agents in preclinical and early clinical development.
Keywords: Sarcoma, AKT, mTOR, IGF-1R, Ras, Apoptosis, VEGF and targeted therapy
Current Drug Targets
Title: Targeting Sarcomas: Novel Biological Agents and Future Perspectives
Volume: 10 Issue: 10
Author(s): Devalingam Mahalingam, Alain Mita, Kamalesh Sankhala, Ronan Swords, Kevin Kelly, Francis Giles and Monica M. Mita
Affiliation:
Keywords: Sarcoma, AKT, mTOR, IGF-1R, Ras, Apoptosis, VEGF and targeted therapy
Abstract: Sarcomas are a group of heterogeneous tumors that arise from mesenchymal tissue and account for approximately 1% of all adult solid malignancies diagnosed, although its incidence approaches 20% in pediatric cancers. Characterization of molecular abnormalities in patients with sarcomas, in particular the up-regulation of the receptor tyrosine kinase and the PI3K-AKT-mTOR pathway, loss or deletions of retinoblastoma (Rb) and p53 gene, increased VEGF expression and angiogenesis, dysregulation of apoptosis through Bcl-2 overexpression, along with oncogene mutations and activations, such as c-KIT in Gastrointestinal stromal tumors (GISTs), makes treatment with novel biological therapies a promising option. This review focuses on the molecular heterogeneity of soft tissue and bone sarcomas, novel biological therapies currently in clinical trials to target the various molecular pathways, and the potential biological agents in preclinical and early clinical development.
Export Options
About this article
Cite this article as:
Mahalingam Devalingam, Mita Alain, Sankhala Kamalesh, Swords Ronan, Kelly Kevin, Giles Francis and Mita M. Monica, Targeting Sarcomas: Novel Biological Agents and Future Perspectives, Current Drug Targets 2009; 10 (10) . https://dx.doi.org/10.2174/138945009789577990
DOI https://dx.doi.org/10.2174/138945009789577990 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antitumor Effects of Celastrol and Semi-Synthetic Derivatives
Mini-Reviews in Organic Chemistry Advanced Development Strategies for Biopharmaceutical Cell Culture Processes
Current Pharmaceutical Biotechnology Therapeutic Application of Natural Medicine Monomers in Cancer Treatment
Current Medicinal Chemistry Roles for Serotonin in Neurodevelopment: More than just Neural Transmission
Current Neuropharmacology Can Colorectal Cancer be Prevented or Treated by Oral Hormone Replacement Therapy?
Current Molecular Pharmacology Role of Nuclear Steroid Receptors in Apoptosis
Current Medicinal Chemistry The Potential Use of RNA-based Therapeutics for Breast Cancer Treatment
Current Medicinal Chemistry SCAP/SREBPs are Central Players in Lipid Metabolism and Novel Metabolic Targets in Cancer Therapy
Current Topics in Medicinal Chemistry Association of Genetic Variants with Colorectal Cancer in the Extended MENA Region: A Systematic Review
Current Molecular Medicine Glutamine, Glucose and other Fuels for Cancer
Current Pharmaceutical Design Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets
Current Genomics Aberrant Splicing, Hyaluronan Synthases and Intracellular Hyaluronan as Drivers of Oncogenesis and Potential Drug Targets
Current Cancer Drug Targets DNA Methylation in Colon Cancer: Challenges and Opportunities
Epigenetic Diagnosis & Therapy (Discontinued) Pharmacology and Therapeutic Applications of Enediyne Antitumor Antibiotics
Current Molecular Pharmacology Editorial [Hot Topic: The RB-Pathway in Cancer (Executive Editor: Erik Knudsen)]
Current Molecular Medicine Targeting the SUMO E2 Conjugating Enzyme Ubc9 Interaction for Anti-Cancer Drug Design
Anti-Cancer Agents in Medicinal Chemistry Gliomas: New Perspectives in Diagnosis, Treatment and Prognosis
Current Topics in Medicinal Chemistry Potential Utilization of Bystander / Abscopal-Mediated Signal Transduction Events in the Treatment of Solid Tumors
Current Signal Transduction Therapy Targeting DNA G-Quadruplex Structures with Peptide Nucleic Acids
Current Pharmaceutical Design The ‘Other’ Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents